{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:16:58Z","timestamp":1788250618193,"version":"build-2803163510"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"University of Sharjah Targeted Research Grant","award":["2301110392"],"award-info":[{"award-number":["2301110392"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>EORTC thresholds for clinical importance on the QLQ-C30 have been proposed to improve the interpretability of patient-reported outcomes (PROs), but their clinical relevance remains underexplored in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the frequency of clinically important baseline PRO domains and their associations with survival and adverse events in patients with CLL\/SLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This was a pooled retrospective analysis of individual patient data from three randomized clinical trials of ibrutinib-based therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were pooled from RESONATE, RESONATE-2, and HELIOS. EORTC thresholds for clinical importance were applied to baseline QLQ-C30 scores to identify clinically important PRO domains. Cox proportional hazards models were used to examine associations between the number of clinically important PRO domains and overall survival (OS), progression-free survival (PFS), and grade \u22653 adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 1,238 patients, 920 (74%) reported at least one clinically important PRO domain and 395 (32%) reported five or more. Each additional clinically important domain was independently associated with worse OS (adjusted HR [95% CI]: 1.07 [1.04\u20131.11]; P &lt; 0.001), worse PFS (1.03 [1.00\u20131.06]; P = 0.047), and increased risk of grade \u22653 adverse events (1.03 [1.01\u20131.06]; P = 0.006). Compared with patients reporting no clinically important PRO domains, those with \u22655 domains had worse OS (2.04 [1.42\u20132.94]; P &lt; 0.001) and higher risk of grade \u22653 adverse events (1.47 [1.17\u20131.85]; P &lt; 0.001). Physical function was the strongest individual prognostic domain for OS (C-index = 0.63).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinically important PRO domains were common among patients with CLL\/SLL initiating ibrutinib-based therapy and were independently associated with survival and toxicity outcomes. These findings support the clinical utility of EORTC QLQ-C30 thresholds for identifying patients with higher baseline PRO burden who may benefit from enhanced risk stratification, supportive care, and individualized treatment planning.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207261480380","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:19:09Z","timestamp":1787923149000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of patient-reported outcome thresholds on survival and adverse events in CLL\/SLL: A pooled analysis of ibrutinib trials"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-065X","authenticated-orcid":false,"given":"Ahmad Y.","family":"Abuhelwa","sequence":"first","affiliation":[{"name":"University of Sharjah"},{"name":"University of Sharjah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Almansour","sequence":"additional","affiliation":[{"name":"University of Sharjah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaid O.","family":"Al-Shamsi","sequence":"additional","affiliation":[{"name":"Burjeel Medical City"},{"name":"Ras Al Khaimah Medical and Health Sciences"},{"name":"Dana-Farber Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Abuhelwa","sequence":"additional","affiliation":[{"name":"University of South Florida\/ H. Lee Moffitt Cancer Center and Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad A.","family":"Ziade","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Medcare Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Bustanji","sequence":"additional","affiliation":[{"name":"University of Sharjah"},{"name":"The University of Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Semreen","sequence":"additional","affiliation":[{"name":"University of Sharjah"},{"name":"University of Sharjah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A. Y.","family":"Alqudah","sequence":"additional","affiliation":[{"name":"University of Sharjah"},{"name":"University of Sharjah"},{"name":"Jordan University of Science and Technology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.","family":"McKinnon","sequence":"additional","affiliation":[{"name":"Flinders University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karem H.","family":"Alzoubi","sequence":"additional","affiliation":[{"name":"Qatar University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[{"name":"Flinders University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Flinders University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26474"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00728-z"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00669-7"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010119"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000510768"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02738"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16859"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.007"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438512"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_200383"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13806"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100475"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33133"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-211613"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5948"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.10.017"},{"key":"e_1_3_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14410"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0348"},{"key":"e_1_3_9_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2019.10.003"},{"key":"e_1_3_9_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmrs.421"},{"key":"e_1_3_9_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06545-7"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.02.059"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00448-8"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0489-4"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18072"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25638"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006434"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1795159"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-022-01987-x"},{"key":"e_1_3_9_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv576"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4427"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.36_suppl.349527"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2015-0014"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-024-03728-7"},{"key":"e_1_3_9_37_2","first-page":"173","article-title":"Moving beyond barriers: a mixed-method study to develop evidence-based strategies to improve implementation of PROMs in clinical oncology care","volume":"1","author":"Boomstra E","year":"2024","unstructured":"Boomstra E, Walraven I, van der Ploeg IM, et al. Moving beyond barriers: a mixed-method study to develop evidence-based strategies to improve implementation of PROMs in clinical oncology care. Quality of Life Research 2024; 1\u201316: 173\u2013188. https:\/\/pubmed.ncbi.nlm.nih.gov\/39302555\/","journal-title":"Quality of Life Research"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/abm\/kax004"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1784120"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01308"},{"key":"e_1_3_9_41_2","first-page":"2497","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd JC","year":"2015","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, The Journal of the American Society of Hematology 2015; 125: 2497\u20132506. https:\/\/doi.org\/10.1182\/blood-2014-10-606038","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"e_1_3_9_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03300-8"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31554"},{"key":"e_1_3_9_44_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107326"},{"key":"e_1_3_9_45_2","first-page":"445","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Gui\u00e8ze R","year":"2015","unstructured":"Gui\u00e8ze R, Wu CJ. Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. Blood, The Journal of the American Society of Hematology 2015; 126: 445\u2013453. https:\/\/doi.org\/10.1182\/blood-2015-02-585042","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"e_1_3_9_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2022.09.047"},{"key":"e_1_3_9_47_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-938"},{"key":"e_1_3_9_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30656-4"},{"issue":"4","key":"e_1_3_9_49_2","first-page":"e70100","article-title":"Physical Activity, Symptoms, Quality of Life and Exercise Program Preferences in People with Chronic Lymphocytic Leukemia","volume":"6","author":"Miles EE","year":"2025","unstructured":"Miles EE, Nicol J, Fowler H, et al. Physical Activity, Symptoms, Quality of Life and Exercise Program Preferences in People with Chronic Lymphocytic Leukemia. medRxiv:2025. 2025; 6(4): e70100. https:\/\/pubmed.ncbi.nlm.nih.gov\/40642445\/","journal-title":"medRxiv:2025"},{"key":"e_1_3_9_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2022.09.002"},{"key":"e_1_3_9_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2471508"},{"key":"e_1_3_9_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-104"},{"key":"e_1_3_9_53_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-019117"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261480380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207261480380","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207261480380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T07:48:11Z","timestamp":1788248891000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207261480380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"alternative-id":["10.1177\/20406207261480380"],"URL":"https:\/\/doi.org\/10.1177\/20406207261480380","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"20406207261480380"}}